PIII icon

P3 Health Partners

7.30 USD
+1.50
25.86%
At close Jul 30, 4:00 PM EDT
After hours
7.60
+0.30
4.11%
1 day
25.86%
5 days
-2.80%
1 month
15.87%
3 months
-18.80%
6 months
-16.57%
Year to date
-41.60%
1 year
-76.46%
5 years
-98.49%
10 years
-98.49%
 

About: P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Employees: 360

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

1.7% less ownership

Funds ownership: 12.42% [Q4 2024] → 10.72% (-1.7%) [Q1 2025]

13% less funds holding

Funds holding: 39 [Q4 2024] → 34 (-5) [Q1 2025]

37% less capital invested

Capital invested by funds: $4.57M [Q4 2024] → $2.9M (-$1.67M) [Q1 2025]

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Research analyst outlook

We haven’t received any recent analyst ratings for PIII.

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Neutral
GlobeNewsWire
1 week ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Neutral
GlobeNewsWire
1 month ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Negative
Zacks Investment Research
1 month ago
Bears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for P3 Health Partners (PIII), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Bears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' Now
Neutral
GlobeNewsWire
1 month ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Neutral
GlobeNewsWire
1 month ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. (NASDAQ: PIII) (“P3” or the “Company”). (NASDAQ: PIII)
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Neutral
GlobeNewsWire
2 months ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Positive
Zacks Investment Research
2 months ago
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
Neutral
GlobeNewsWire
2 months ago
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Wolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.
Neutral
Seeking Alpha
2 months ago
P3 Health Partners Inc. (PIII) Q1 2025 Earnings Call Transcript
P3 Health Partners Inc. (NASDAQ:PIII ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ryan Halstead - Managing Director, Gilmartin Group LLC, IR Aric Coffman - CEO Leif Pedersen - CFO Amir Bacchus - Chief Medical Officer Conference Call Participants Josh Raskin - Nephron Research Ryan Langston - TD Cowen Operator Good day, and welcome to the P3 Health Partners First Quarter 2025 Earnings Conference Call. All participants will be in listen-only-mode.
P3 Health Partners Inc. (PIII) Q1 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™